These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12620743)
21. [How far away is the first anti-HIV vaccine?]. Bürk RR Fortschr Med; 1994 Mar; 112(7):61-2. PubMed ID: 8175095 [No Abstract] [Full Text] [Related]
22. HIV-vaccine research and development in Thailand: evolution and challenges. Pitisuttithum P; Choopanya K; Rerk-Ngnam S Vaccine; 2010 May; 28 Suppl 2():B45-9. PubMed ID: 20510743 [TBL] [Abstract][Full Text] [Related]
23. HIV-1 T-cell vaccines: evaluating the next step. Pantaleo G Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842 [No Abstract] [Full Text] [Related]
24. Controversial HIV vaccine enters phase III trials amid skepticism. AIDS Alert; 1998 Dec; 13(12):133-4, 136. PubMed ID: 11366059 [TBL] [Abstract][Full Text] [Related]
25. Support for the RV144 HIV vaccine trial. AIDS Vaccine Advocacy Coalition Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069 [No Abstract] [Full Text] [Related]
26. HIV vaccine failure prompts Merck to halt trial. Nature; 2007 Sep; 449(7161):390. PubMed ID: 17898737 [No Abstract] [Full Text] [Related]
27. Vaccine-induced HIV seropositivity: a problem on the rise. Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566 [TBL] [Abstract][Full Text] [Related]
32. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Marovich MA Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S99-104. PubMed ID: 15285709 [TBL] [Abstract][Full Text] [Related]
33. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
34. Phase II prime-boost trial begins in the U.S. McEnery R IAVI Rep; 2009; 13(4):18. PubMed ID: 20225577 [No Abstract] [Full Text] [Related]
35. Combo of two HIV vaccines fails its big test. Cohen J Science; 2020 Feb; 367(6478):611-612. PubMed ID: 32029605 [No Abstract] [Full Text] [Related]
36. In search of a human immunodeficiency virus vaccine. Bartholomew CF West Indian Med J; 2000 Sep; 49(3):187-9. PubMed ID: 11076204 [No Abstract] [Full Text] [Related]
37. Statistical evaluation of HIV vaccines in early clinical trials. Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900 [TBL] [Abstract][Full Text] [Related]
38. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. Robinson HL; Weinhold KJ J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331 [No Abstract] [Full Text] [Related]
39. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary. Gorse GJ AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S141-3. PubMed ID: 7865289 [No Abstract] [Full Text] [Related]
40. Response to Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. Halpern SD J Acquir Immune Defic Syndr; 2003 Jul; 33(3):412. PubMed ID: 12843757 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]